Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

The HER2 CISH pharmDx(™) Kit in the assessment of breast cancer patients for anti-HER2 treatment.

Foged NT, Brügmann A, Jørgensen JT.

Expert Rev Mol Diagn. 2013 Apr;13(3):233-42. doi: 10.1586/erm.13.6.

PMID:
23570400
2.

Screening of subfertile men for testicular carcinoma in situ by an automated image analysis-based cytological test of the ejaculate.

Almstrup K, Lippert M, Mogensen HO, Nielsen JE, Hansen JD, Daugaard G, Jørgensen N, Foged NT, Skakkebaek NE, Rajpert-De Meyts E.

Int J Androl. 2011 Aug;34(4 Pt 2):e21-30; discussion e30-1. doi: 10.1111/j.1365-2605.2011.01192.x. Epub 2011 Jun 22.

PMID:
21696398
3.

Digital image analysis of membrane connectivity is a robust measure of HER2 immunostains.

Brügmann A, Eld M, Lelkaitis G, Nielsen S, Grunkin M, Hansen JD, Foged NT, Vyberg M.

Breast Cancer Res Treat. 2012 Feb;132(1):41-9. doi: 10.1007/s10549-011-1514-2. Epub 2011 Apr 22.

PMID:
21512768
4.

Practical considerations of image analysis and quantification of signal transduction IHC staining.

Grunkin M, Raundahl J, Foged NT.

Methods Mol Biol. 2011;717:143-54. doi: 10.1007/978-1-61779-024-9_8.

PMID:
21370029
5.

Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue.

Sorensen IV, Fenger C, Winther H, Foged NT, Lademann U, Brünner N, Usher PA.

J Histochem Cytochem. 2006 Oct;54(10):1075-86. Epub 2006 Mar 3.

6.

A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cells.

Andersen TL, del Carmen Ovejero M, Kirkegaard T, Lenhard T, Foged NT, Delaissé JM.

Bone. 2004 Nov;35(5):1107-19.

PMID:
15542036
7.

The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation.

Schaller S, Henriksen K, Sveigaard C, Heegaard AM, Hélix N, Stahlhut M, Ovejero MC, Johansen JV, Solberg H, Andersen TL, Hougaard D, Berryman M, Shiødt CB, Sørensen BH, Lichtenberg J, Christophersen P, Foged NT, Delaissé JM, Engsig MT, Karsdal MA.

J Bone Miner Res. 2004 Jul;19(7):1144-53. Epub 2004 Mar 1. Erratum in: J Bone Miner Res. 2004 Aug;19(8):1378.

8.

Matrix metalloproteinase-12 (MMP-12) in osteoclasts: new lesson on the involvement of MMPs in bone resorption.

Hou P, Troen T, Ovejero MC, Kirkegaard T, Andersen TL, Byrjalsen I, Ferreras M, Sato T, Shapiro SD, Foged NT, Delaissé JM.

Bone. 2004 Jan;34(1):37-47.

PMID:
14751561
9.

Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression.

Karsdal MA, Hjorth P, Henriksen K, Kirkegaard T, Nielsen KL, Lou H, Delaissé JM, Foged NT.

J Biol Chem. 2003 Nov 7;278(45):44975-87. Epub 2003 Aug 20.

10.

The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation.

Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, Qvist P, Delmas PD, Foged NT, Delaissé JM.

J Bone Miner Res. 2003 May;18(5):859-67.

11.

Estradiol enhances osteolytic lesions in mice inoculated with human estrogen receptor-negative MDA-231 breast cancer cells in vivo.

Winding B, Misander H, Høegh-Andersen P, Brünner N, Foged NT.

Breast Cancer Res Treat. 2003 Mar;78(2):205-16.

PMID:
12725420
12.

Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis.

Karsdal MA, Larsen L, Engsig MT, Lou H, Ferreras M, Lochter A, Delaissé JM, Foged NT.

J Biol Chem. 2002 Nov 15;277(46):44061-7. Epub 2002 Sep 10.

13.

Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice.

Winding B, NicAmhlaoibh R, Misander H, Høegh-Andersen P, Andersen TL, Holst-Hansen C, Heegaard AM, Foged NT, Brünner N, Delaissé JM.

Clin Cancer Res. 2002 Jun;8(6):1932-9.

14.
15.

Phosphinic peptide inhibitors of macrophage metalloelastase (MMP-12). Selectivity and mechanism of binding.

Schiødt CB, Buchardt J, Terp GE, Christensen U, Brink M, Berger Larsen Y, Meldal M, Foged NT.

Curr Med Chem. 2001 Jul;8(8):967-76.

PMID:
11375764
16.

Solid phase combinatorial library of phosphinic peptides for discovery of matrix metalloproteinase inhibitors.

Buchardt J, Schiødt CB, Krog-Jensen C, Delaissé JM, Foged NT, Meldal M.

J Comb Chem. 2000 Nov-Dec;2(6):624-38.

PMID:
11138549
17.

Human breast cancer cells induced angiogenesis, recruitment, and activation of osteoclasts in osteolytic metastasis.

Winding B, Misander H, Sveigaard C, Therkildsen B, Jakobsen M, Overgaard T, Oursler MJ, Foged NT.

J Cancer Res Clin Oncol. 2000 Nov;126(11):631-40.

PMID:
11079727
18.

Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones.

Engsig MT, Chen QJ, Vu TH, Pedersen AC, Therkidsen B, Lund LR, Henriksen K, Lenhard T, Foged NT, Werb Z, Delaissé JM.

J Cell Biol. 2000 Nov 13;151(4):879-89. Erratum in: J Cell Biol 2001 Jan 22;152(2):following 417.

19.

Quantification of osteoclastic resorption of the bovine otic capsule in vitro by an enzyme-linked immunosorbent assay.

Frisch T, Foged NT, Sørensen MS, Bretlau P.

ORL J Otorhinolaryngol Relat Spec. 2000 Sep-Oct;62(5):235-40.

PMID:
10965257
20.

Proteinases in bone resorption: obvious and less obvious roles.

Delaissé JM, Engsig MT, Everts V, del Carmen Ovejero M, Ferreras M, Lund L, Vu TH, Werb Z, Winding B, Lochter A, Karsdal MA, Troen T, Kirkegaard T, Lenhard T, Heegaard AM, Neff L, Baron R, Foged NT.

Clin Chim Acta. 2000 Feb 15;291(2):223-34. Review.

PMID:
10675725
21.

Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity.

Pederson L, Winding B, Foged NT, Spelsberg TC, Oursler MJ.

Cancer Res. 1999 Nov 15;59(22):5849-55.

22.

The collagenolytic activity of cathepsin K is unique among mammalian proteinases.

Garnero P, Borel O, Byrjalsen I, Ferreras M, Drake FH, McQueney MS, Foged NT, Delmas PD, Delaissé JM.

J Biol Chem. 1998 Nov 27;273(48):32347-52.

23.

PEGA supports for combinatorial peptide synthesis and solid-phase enzymatic library assays.

Renil M, Ferreras M, Delaisse JM, Foged NT, Meldal M.

J Pept Sci. 1998 May;4(3):195-210.

PMID:
9643628
24.

[Effects of progesterone on proliferation and differentiation of fetal rat calvarial osteoblasts in vitro].

Chen L, Schøller J, Foged NT.

Zhonghua Fu Chan Ke Za Zhi. 1997 Sep;32(9):538-40. Chinese.

PMID:
9639754
25.
27.

Evidence of a correlation of estrogen receptor level and avian osteoclast estrogen responsiveness.

Pederson L, Kremer M, Foged NT, Winding B, Ritchie C, Fitzpatrick LA, Oursler MJ.

J Bone Miner Res. 1997 May;12(5):742-52.

28.

Identification and characterization of the insulin-like growth factor I receptor in mature rabbit osteoclasts.

Hou P, Sato T, Hofstetter W, Foged NT.

J Bone Miner Res. 1997 Apr;12(4):534-40.

29.

Identification of the membrane-type matrix metalloproteinase MT1-MMP in osteoclasts.

Sato T, del Carmen Ovejero M, Hou P, Heegaard AM, Kumegawa M, Foged NT, Delaissé JM.

J Cell Sci. 1997 Mar;110 ( Pt 5):589-96.

30.

Induction of osteocalcin gene expression in vitro by progesterone.

Chen L, Foged NT.

J Tongji Med Univ. 1997;17(2):72-4.

PMID:
9639792
32.

Quantification of the collagenolytic activity of isolated osteoclasts by enzyme-linked immunosorbent assay.

Foged NT, Delaissé JM, Hou P, Lou H, Sato T, Winding B, Bonde M.

J Bone Miner Res. 1996 Feb;11(2):226-37.

PMID:
8822347
33.

Differentiation of osteoblast in vitro is regulated by progesterone.

Chen L, Foged NT.

J Tongji Med Univ. 1996;16(2):83-6.

PMID:
9275698
34.

ALP induction by beta-glycerophosphate during the non-mineralization phase in vitro.

Chen L, Schøller J, Foged NT.

J Tongji Med Univ. 1996;16(1):20-4.

PMID:
8758739
35.
37.

Characterization of the immunogenicity of formaldehyde detoxified Pasteurella multocida toxin.

Bording A, Foged NT.

Vet Microbiol. 1991 Nov;29(3-4):267-80.

PMID:
1771750
39.

Characterization of toxin from different strains of Pasteurella multocida serotype A and D.

Frandsen PL, Foged NT, Petersen SK, Bording A.

Zentralbl Veterinarmed B. 1991 Jul;38(5):345-52.

PMID:
1927149
40.

Ultrastructural localization of the Pasteurella multocida toxin in a toxin-producing strain.

iDali C, Foged NT, Frandsen PL, Nielsen MH, Elling F.

J Gen Microbiol. 1991 May;137(5):1067-71.

PMID:
1865180
41.
42.

Vaccination against progressive atrophic rhinitis with a recombinant Pasteurella multocida toxin derivative.

Nielsen JP, Foged NT, Sørensen V, Barfod K, Bording A, Petersen SK.

Can J Vet Res. 1991 Apr;55(2):128-38.

43.

Recombinant derivatives of Pasteurella multocida toxin: candidates for a vaccine against progressive atrophic rhinitis.

Petersen SK, Foged NT, Bording A, Nielsen JP, Riemann HK, Frandsen PL.

Infect Immun. 1991 Apr;59(4):1387-93.

44.

Heat-labile toxin-producing isolates of Pasteurella multocida from rabbits.

Suckow MA, Chrisp CE, Foged NT.

Lab Anim Sci. 1991 Apr;41(2):151-6.

PMID:
1658444
45.
46.
47.
49.
50.

Atrophic rhinitis in pigs: proposal for a revised definition.

Pedersen KB, Nielsen JP, Foged NT, Elling F, Nielsen NC, Willeberg P.

Vet Rec. 1988 Feb 20;122(8):190-1. No abstract available.

PMID:
3358289

Supplemental Content

Loading ...
Support Center